The determination and interpretation of the therapeutic index in drug development

被引:384
作者
Muller, Patrick Y. [1 ]
Milton, Mark N. [1 ]
机构
[1] Novartis Inst BioMed Res, Cambridge, MA 02139 USA
关键词
PLASMA-PROTEIN BINDING; INDUCED LIVER-INJURY; IN-VITRO INHIBITION; SALT EXPORT PUMP; SAFETY ASSESSMENT; CLINICAL-TRIALS; TOXICITY; PREDICTION; ADVERSE; ALBUMIN;
D O I
10.1038/nrd3801
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
A key part of drug discovery and development is the characterization and optimization of the safety and efficacy of drug candidates to identify those that have an appropriately balanced safety-efficacy profile for a given indication. The therapeutic index (TI) - which is typically considered as the ratio of the highest exposure to the drug that results in no toxicity to the exposure that produces the desired efficacy - is an important parameter in efforts to achieve this balance. Various types of safety and efficacy data are generated in vitro and in vivo (in animals and in humans), and these data can be used to predict the clinical TI of a drug candidate at an early stage. However, approaches to systematically and quantitatively compare these types of data and to apply this knowledge more effectively are needed. This article critically discusses the various aspects of TI determination and interpretation in drug development for both small molecule drugs and biotherapeutics.
引用
收藏
页码:751 / 761
页数:11
相关论文
共 55 条
  • [1] [Anonymous], 1997, ICH HARM TRIP GUID T
  • [2] [Anonymous], 2012, AVAILABILITY FED REG
  • [3] [Anonymous], 2005, ICH HARM TRIP GUID N
  • [4] Analysis of pharmacology data and the prediction of adverse drug reactions and off-target effects from chemical structure
    Bender, Andreas
    Scheiber, Josef
    Glick, Meir
    Davies, John W.
    Azzaoui, Kamal
    Hamon, Jacques
    Urban, Laszlo
    Whitebread, Steven
    Jenkins, Jeremy L.
    [J]. CHEMMEDCHEM, 2007, 2 (06) : 861 - 873
  • [5] CLOZEL M, 1994, J PHARMACOL EXP THER, V270, P228
  • [6] CORDES J, 2009, J PHARMACOL TOXICOL, V60, P221, DOI DOI 10.1016/j.vascn.2009.04.059
  • [7] Cui YX, 2010, PHARMACOGENOMICS, V11, P573, DOI [10.2217/pgs.10.37, 10.2217/PGS.10.37]
  • [8] Dajani EZ, 2008, J PHYSIOL PHARMACOL, V59, P117
  • [9] In Vitro Inhibition of the Bile Salt Export Pump Correlates with Risk of Cholestatic Drug-Induced Liver Injury in Humans
    Dawson, Sarah
    Stahl, Simone
    Paul, Nikki
    Barber, Jane
    Kenna, J. Gerald
    [J]. DRUG METABOLISM AND DISPOSITION, 2012, 40 (01) : 130 - 138
  • [10] In silico prediction of drug toxicity
    Dearden, JC
    [J]. JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN, 2003, 17 (02) : 119 - 127